Supporting his treatment right from the start

The more your patient knows about Novoeight®, the better equipped he will be to play an active role in his treatment plan. Here are some resources that can help you initiate discussions about the features of Novoeight® and engage him in the treatment process:

Novoeight start guide
Novoeight Counsel The Switch


 



 

Contact a Novoeight hemophilia therapy sales manager

Talk with us

Connect with a local Novo Nordisk Representative to learn more about Novoeight®. He or she is an excellent source for information, and can direct you to many helpful tools and resources.

 


 



 

NovoSecure™ patient support program

Patient support

NovoSecure™ offers a range of support to help get your patient where he wants to be, regardless of his choice of treatment.

Novo Nordisk student scholarships

Educational scholarships

Novo Nordisk offers the opportunity for students with bleeding disorders, regardless of treatment choice, to compete for scholarships to help them achieve their educational goals.


 



 

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.
 

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.


Please click here for Novoeight® Prescribing Information.